- Home
- THAR
THAR
Tharimmune Inc.
as 11-04-2025 4:00pm EST
Tharimmune Inc is a biotechnology company developing a portfolio of therapeutic candidates for rare immune, inflammatory, and oncologic diseases. The Company is progressing towards acquiring a clinical-stage asset known to suppress chronic, debilitating pruritis or uncontrollable itching in primary biliary cholangitis (PBC), a rare orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting epitopes with novel mechanisms of action against validated targets in multiple solid tumors.
Upcoming Earnings Alert:
Get ready for potential market movements as Tharimmune Inc. THAR prepares to release earnings report on 07 Nov 2025.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | BRIDGEWATER |
| Market Cap: | 22.8M | IPO Year: | 2022 |
| Target Price: | $17.00 | AVG Volume (30 days): | 2.6M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.95 - $9.08 | Next Earning Date: | 11-07-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Tharimmune Inc. News
THAR Breaking Stock News: Dive into THAR Ticker-Specific Updates for Smart Investing
ACCESS Newswire
5 months ago
Tharimmune Announces Key Leadership Appointments Including James Gordon Liddy Joining Board of Directors
ACCESS Newswire
6 months ago
Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
ACCESS Newswire
6 months ago
Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback
ACCESS Newswire
6 months ago
Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences
ACCESS Newswire
6 months ago
Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors
ACCESS Newswire
6 months ago
Tharimmune Advances TH104 for Prophylaxis Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback
ACCESS Newswire
7 months ago
Tharimmune Strengthens Strategic Leadership with the Appointment of Vincent LoPriore to its Board of Directors
ACCESS Newswire
7 months ago
Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Compare THAR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "THAR Tharimmune Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.